{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T17:41:43Z","timestamp":1787938903947,"version":"build-2784847793"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40266-025-01261-x","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:27:17Z","timestamp":1761740837000},"page":"69-76","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Initial Real-World Evidence for Lecanemab in the United States"],"prefix":"10.1007","volume":"43","author":[{"given":"Diana I.","family":"Brixner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyue","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Toyosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feride H.","family":"Frech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Rosenbloom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"5","key":"1261_CR1","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","volume":"20","author":"A Association","year":"2024","unstructured":"Association A. 2024 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2024;20(5):3708\u2013821.","journal-title":"Alzheimers Dement"},{"key":"1261_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117996","volume":"256","author":"A Abeysinghe","year":"2020","unstructured":"Abeysinghe A, Deshapriya R, Udawatte C. Alzheimer\u2019s disease; a review of the pathophysiological basis and therapeutic interventions. Life Sci. 2020;256:117996.","journal-title":"Life Sci"},{"issue":"1","key":"1261_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12877-018-0855-7","volume":"18","author":"C Barbe","year":"2018","unstructured":"Barbe C, Jolly D, Morrone I, et al. Factors associated with quality of life in patients with Alzheimer\u2019s disease. BMC Geriatr. 2018;18(1):159.","journal-title":"BMC Geriatr"},{"issue":"1","key":"1261_CR4","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1080\/13696998.2021.1927747","volume":"24","author":"C Makin","year":"2021","unstructured":"Makin C, Neumann P, Peschin S, Goldman D. Modelling the value of innovative treatments for Alzheimer\u2019s disease in the United States. J Med Econ. 2021;24(1):764\u20139.","journal-title":"J Med Econ"},{"issue":"8 Suppl","key":"1261_CR5","first-page":"S167","volume":"26","author":"RA Marasco","year":"2020","unstructured":"Marasco RA. Current and evolving treatment strategies for the Alzheimer disease continuum. Am J Manag Care. 2020;26(8 Suppl):S167\u201376.","journal-title":"Am J Manag Care"},{"issue":"8","key":"1261_CR6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.nrl.2016.02.023","volume":"32","author":"FJ Garzon-Maldonado","year":"2017","unstructured":"Garzon-Maldonado FJ, Gutierrez-Bedmar M, Garcia-Casares N, Perez-Errazquin F, Gallardo-Tur A, Martinez-Valle Torres MD. Health-related quality of life in caregivers of patients with Alzheimer\u2019s disease. Neurologia. 2017;32(8):508\u201315.","journal-title":"Neurologia"},{"issue":"4","key":"1261_CR7","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s40273-019-00788-3","volume":"37","author":"PJ Lin","year":"2019","unstructured":"Lin PJ, D\u2019Cruz B, Leech AA, et al. Family and caregiver spillover effects in cost-utility analyses of Alzheimer\u2019s disease interventions. Pharmacoeconomics. 2019;37(4):597\u2013608.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"1261_CR8","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/alz.12362","volume":"17","author":"KB Rajan","year":"2021","unstructured":"Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA. Population estimate of people with clinical Alzheimer\u2019s disease and mild cognitive impairment in the United States (2020\u20132060). Alzheimers Dement. 2021;17(12):1966\u201375.","journal-title":"Alzheimers Dement"},{"key":"1261_CR9","unstructured":"He W, Goodkind D, Kowal P. U.S. Census Bureau, International Population Reports, P95\/16-1, An Aging World: 2015, U.S. Government Publishing Office, Washington, DC. 2016. https:\/\/www.census.gov\/content\/dam\/Census\/library\/publications\/2016\/demo\/p95-16-1.pdf. Accessed 26 Jan 2022."},{"key":"1261_CR10","unstructured":"Alzheimer's Association. 2018 Alzheimer's disease facts and figures. 2018. https:\/\/www.alz.org\/media\/homeoffice\/facts%20and%20figures\/facts-and-figures.pdf. Accessed 10 Feb 2022."},{"issue":"2","key":"1261_CR11","first-page":"67","volume":"44","author":"NI Bradfield","year":"2020","unstructured":"Bradfield NI, Ames D. Mild cognitive impairment: narrative review of taxonomies and systematic review of their prediction of incident Alzheimer\u2019s disease dementia. Br J Psych Bull. 2020;44(2):67\u201374.","journal-title":"Br J Psych Bull"},{"key":"1261_CR12","first-page":"123","volume":"9","author":"J Rasmussen","year":"2019","unstructured":"Rasmussen J, Langerman H. Alzheimer\u2019s disease\u2014why we need early diagnosis. Degener Neurol Neuromuscul Dis. 2019;9:123\u201330.","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"1261_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2024.100035","volume":"12","author":"CG Cox","year":"2025","unstructured":"Cox CG, Brush BL, Kobayashi LC, Roberts JS. Determinants of dementia diagnosis in US primary care in the past decade: a scoping review. J Prev Alzheimers Dis. 2025;12:100035.","journal-title":"J Prev Alzheimers Dis"},{"key":"1261_CR14","unstructured":"LEQEMBI\u2122 (lecanemab-irmb) injection, for intravenous use [package insert]. Nutley, NJ: Eisai Inc."},{"key":"1261_CR15","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021;13:80.","journal-title":"Alzheimers Res Ther"},{"key":"1261_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"1261_CR17","doi-asserted-by":"publisher","first-page":"771","DOI":"10.14283\/jpad.2023.123","volume":"10","author":"S Cohen","year":"2023","unstructured":"Cohen S, van Dyck CH, Gee M, et al. Lecanemab clarity AD: quality-of-life results from a randomized, double-blind phase 3 trial in early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2023;10:771\u20137. https:\/\/doi.org\/10.14283\/jpad.2023.123.","journal-title":"J Prev Alzheimers Dis"},{"key":"1261_CR18","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3233\/JAD-140741","volume":"43","author":"S Tucker","year":"2015","unstructured":"Tucker S, M\u00f6ller C, Tegerstedt K, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43:575\u201388.","journal-title":"J Alzheimers Dis"},{"key":"1261_CR19","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"L S\u00f6derberg","year":"2023","unstructured":"S\u00f6derberg L, Johannesson M, Nygren P, et al. Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease. Neurotherapeutics. 2023;20:195\u2013206.","journal-title":"Neurotherapeutics"},{"key":"1261_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/JAD-130029","volume":"37","author":"K Magnusson","year":"2013","unstructured":"Magnusson K, Sehlin D, Syv\u00e4nen S, et al. Specific uptake of an amyloid-\u03b2-protofibril-binding antibody-tracer in A\u03b2PP transgenic mouse brain. J Alzheimers Dis. 2013;37:29\u201340.","journal-title":"J Alzheimers Dis"},{"key":"1261_CR21","unstructured":"PurpleLab. PurpleLab Guidebook. 2024. https:\/\/purplelab.com\/wp-content\/uploads\/2024\/10\/PurpleLab-Guidebook-Final-.pdf. Accessed Jan 2025."},{"key":"1261_CR22","unstructured":"Coding for Lecanemab. https:\/\/www.eisaipatientsupport.com\/-\/media\/Files\/PatientSupport\/Coding-Quick-Ref-Guide.pdf. Accessed Sept 2025."},{"key":"1261_CR23","unstructured":"United States Census Bureau. 2020 Census Results. https:\/\/www.census.gov\/programs-surveys\/decennial-census\/decade\/2020\/2020-census-results.html. Accessed Sept 2025."},{"key":"1261_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13854046.2024.2345925","volume":"39","author":"S Uysal","year":"2025","unstructured":"Uysal S. Diagnostic coding of neurocognitive disorders: a roadmap to ICD-10-CM. Clin Neuropsychol. 2025;39:1\u201316.","journal-title":"Clin Neuropsychol"},{"key":"1261_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WAD.0000000000000600","volume":"38","author":"KS Frederiksen","year":"2024","unstructured":"Frederiksen KS, Morat\u00f3 X, Zetterberg H, et al. Focusing on earlier management of Alzheimer disease: expert opinion based on a modified nominal group technique. Alzheimer Dis Assoc Disord. 2024;38:1\u20137.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1261_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70100","volume":"21","author":"N Li","year":"2025","unstructured":"Li N, Borate SN, Zhang K, et al. Mapping disparities in access to lecanemab in Georgia. Alzheimers Dement. 2025;21:e70100.","journal-title":"Alzheimers Dement"},{"key":"1261_CR27","doi-asserted-by":"publisher","first-page":"e169","DOI":"10.37765\/ajmc.2024.89563","volume":"30","author":"N Li","year":"2024","unstructured":"Li N, Rawal S, Young HN, Villa ZL. Innovation, affordability, access: Alzheimer disease drugs and the inflation reduction act. Am J Manag Care. 2024;30:e169\u201371.","journal-title":"Am J Manag Care"},{"issue":"1","key":"1261_CR28","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13195-023-01272-z","volume":"15","author":"S Mattke","year":"2023","unstructured":"Mattke S, Jun H, Chen E, Liu Y, Becker A, Wallick C. Expected and diagnosed rates of mild cognitive impairment and dementia in the US Medicare population: observational analysis. Alzheimers Res Ther. 2023;15(1):128.","journal-title":"Alzheimers Res Ther."},{"key":"1261_CR29","unstructured":"van Dyck CH, Sperling R, Johnson K, et al. Lecanemab for the treatment of early Alzheimer\u2019s disease: extension of efficacy and biomarker results from Clarity AD and the Downstream Implications of Targeting Tau. In: Presented at the American Academy of Neurology (AAN) 2024 annual meeting. April 13\u201318, 2024. Denver, CO, USA [abstract number: 5590, Poster #9]."},{"key":"1261_CR30","doi-asserted-by":"crossref","unstructured":"Charil A, Cao Y, Willis BA, et al. Lecanemab slows Tau PET accumulation. In: Presented at the 2024 Alzheimer's Association international conference (AAIC). July 28\u2013August 1, 2024\/ Philadelphia, PA, USA [abstract number: 91956].","DOI":"10.1002\/alz.091956"},{"key":"1261_CR31","doi-asserted-by":"crossref","unstructured":"van Dyck CH, Sperling R, Shobha Dhadda S, et al. Is there evidence for a continued benefit for long-term lecanemab treatment? A benefit\/risk update from long-term efficacy, safety and biomarker data presented at the 2024 Alzheimer's Association international conference (AAIC). July 28\u2013August 1, 2024\/Philadelphia, PA, USA. [abstract number: 92094].","DOI":"10.1002\/alz.092094"},{"key":"1261_CR32","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/alz.12123","volume":"16","author":"M Kivipelto","year":"2020","unstructured":"Kivipelto M, Mangialasche F, Snyder HM, et al. A global approach to risk reduction and prevention of dementia. Alzheimers Dement. 2020;16:1078\u201394.","journal-title":"Alzheimers Dement"},{"key":"1261_CR33","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404:572\u2013628.","journal-title":"Lancet"},{"key":"1261_CR34","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1002\/alz.13612","volume":"20","author":"L Hinton","year":"2024","unstructured":"Hinton L, Tran D, Peak K, Meyer OL, Qui\u00f1ones AR. Mapping racial and ethnic healthcare disparities for persons living with dementia: a scoping review. Alzheimers Dement. 2024;20:3000\u201320.","journal-title":"Alzheimers Dement"},{"issue":"15_supplement","key":"1261_CR35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1212\/WNL.94.15_supplement.727","volume":"94","author":"K Curtis","year":"2020","unstructured":"Curtis K, Elrahi S, Bilello J, Rai P. Geographical distribution of neurologists in the United States. Neurology. 2020;94(15_supplement):727.","journal-title":"Neurology"},{"key":"1261_CR36","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321:1286\u201394.","journal-title":"JAMA"},{"key":"1261_CR37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.juro.2013.04.048","volume":"190","author":"EK Johnson","year":"2013","unstructured":"Johnson EK, Nelson CP. Values and pitfalls of the use of administrative databases for outcomes assessment. J Urol. 2013;190:17\u20138.","journal-title":"J Urol"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01261-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-025-01261-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-025-01261-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T14:28:03Z","timestamp":1769696883000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-025-01261-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1261"],"URL":"https:\/\/doi.org\/10.1007\/s40266-025-01261-x","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DIB reports personal fees from Eisai during the conduct of the study. MHR reports personal fees from Eisai, outside the submitted work. CZ, HT, and FHF are employees of Eisai.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}